VolitionRX Ltd (A:VNRX)

Mar 25, 2024 04:10 pm ET
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time
Mar 21, 2024 08:30 am ET
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time
Feb 02, 2024 07:00 am ET
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
HENDERSON, Nev., Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.
Jan 04, 2024 07:00 am ET
Volition Issues Business Review 2023
HENDERSON, Nev., Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.
Dec 05, 2023 10:25 am ET
Sidoti Events, LLC's Virtual December Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December 6-7, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Dec 05, 2023 07:00 am ET
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
HENDERSON, Nev., Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium.
Nov 14, 2023 03:10 pm ET
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Wednesday, November 15, at 8:30 a.m. U.S. Eastern Time
Nov 08, 2023 07:00 am ET
VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update
Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time
Nov 06, 2023 05:21 am ET
Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland
HENDERSON, Nev., Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.
Oct 23, 2023 08:00 am ET
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
HENDERSON, Nev., Oct. 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology.
Oct 19, 2023 08:00 am ET
Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock
HENDERSON, Nev., Oct. 19, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis.
Oct 18, 2023 12:00 pm ET
US Ambassador Adler visits Belgian Volition
HENDERSON, Nev., Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes, Belgium.
Oct 16, 2023 08:00 am ET
Volition Presents Three Cancer Detection Abstracts at ESMO 2023
HENDERSON, Nev., Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology.
Oct 13, 2023 08:00 am ET
Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis
HENDERSON, Nev., Oct. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader ("KOL") roundtable on sepsis management.
Oct 02, 2023 08:00 am ET
Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar
HENDERSON, Nev., Oct. 2, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21st at ESMO 2023, the annual congress of the European Society for Medical Oncology.
Sep 13, 2023 08:00 am ET
Volition Hosts Key Opinion Leader Roundtable on Sepsis Management
HENDERSON, Nev., Sept. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a Key Opinion Leader ("KOL") roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis.
Jun 23, 2023 04:10 pm ET
VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters
HENDERSON, Nev., June 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to Volition from the offering to approximately $19.0 million, before deducting underwriting commissions and other offering expenses payable by Volition. All of the shares of common stock sold in the offering, inc
Jun 05, 2023 04:10 pm ET
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million, before deducting underwriting commissions and other offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition.
Jun 01, 2023 09:15 am ET
VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $16.5 million. In addition, Volition has granted the underwriters a 30-day option to purchase up to an additional 1,950,0
May 31, 2023 04:01 pm ET
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
HENDERSON, Nev., May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are being offered by Volition. The final ter
May 11, 2023 07:00 am ET
Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring
HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers.
May 10, 2023 04:10 pm ET
VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time
May 05, 2023 08:00 am ET
VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update
Conference call to take place on Thursday May 11 at 08:30 a.m. Eastern Time
Apr 26, 2023 07:30 am ET
VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.
HENDERSON, Nev., April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 11, 2023, at 2 p.m. U.S. Eastern Time. Volition's executive team will be joined by Key Opinion Leaders: Dr. Andy Retter (Intensive Care Consultant) and Veterinary Oncologists, Professor Heather Wilson-Robles and Dr. Sue Ettinger, aka Dr. Sue Cancer Vet.
Apr 24, 2023 09:00 am ET
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
LAS VEGAS, NV / ACCESSWIRE / April 24, 2023 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 25-27, 2023, where 77 MicroCap public and private companies will be presenting at the Horseshoe Hotel & Casino in Las Vegas, NV.
Mar 20, 2023 02:00 pm ET
Sidoti's Small-Cap Virtual March Conference
NEW YORK, NY / ACCESSWIRE / March 20, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023. The links can also be found at www.sidoticonference.com/events.
Mar 15, 2023 04:10 pm ET
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time
Mar 10, 2023 08:35 am ET
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held on March 9th are now available for online viewing. REGISTER NOW AT:...
Mar 07, 2023 08:35 am ET
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum to be held March 9th. Individual investors, institutional investors, advisors, and analysts...
Mar 06, 2023 04:30 pm ET
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th
VolitionRx Limited (NYSE AMERICAN: VNRX), a multi-national epigenetics company, today announced that Scott Powell, Vice President of Investor Relations at VolitionRx Limited and Chief Investment Officer of Volition America, will present live at the...
Feb 17, 2023 07:30 am ET
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., Feb. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $7.525 million. In addition, Volition has granted the underwriter a 30-day option to purchase up to an additional 645,000
Feb 16, 2023 03:10 pm ET
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
HENDERSON, Nev., Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are being offered by Volition. The final ter
Feb 16, 2023 07:00 am ET
Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation
HENDERSON, Nev., Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation (NASDAQ: HSKA) ("Heska"). The Nu.Q® test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference, one of the world's largest veterinary conferences.
Feb 14, 2023 09:30 am ET
Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences
NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and Thursday, March 22-23, 2023, and the May Virtual Micro-Cap Conference will be on Wednesday and Thursday, May 10-11, 2023.Sidoti hosts eight virtual investor conferences a year, alternating between small- and micro-cap targeted companies. Companies can host both group pr
Jan 20, 2023 07:30 am ET
Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar
HENDERSON, Nev., Jan. 20, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition's Nu.Q® Vet commercial strategy.
Jan 17, 2023 10:00 am ET
Sidoti's January Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can also be found at www.sidoticonference.com/events.
Jan 12, 2023 07:00 am ET
Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network
HENDERSON, Nev., Jan. 12, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. ("IDEXX") reference laboratory network in the U.S.
Jan 08, 2023 11:00 am ET
Volition Issues Business Review 2022
HENDERSON, Nev, Jan. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations.
Nov 14, 2022 03:10 pm ET
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Tuesday, November 15, at 8:30 a.m. U.S. Eastern Time
Nov 14, 2022 07:30 am ET
Volition Announces Clinical Research Study with Oncovet
HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
Nov 10, 2022 07:30 am ET
Volition to Participate in a Lung Cancer Screening Study in France
HENDERSON, Nev., Nov. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has been invited to participate in a government-backed prospective study to evaluate the performance of blood biomarkers in the early detection of lung cancer with Hospices Civils de Lyon ("HCL"), France's second largest university hospital.
Nov 03, 2022 08:30 am ET
Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories
HENDERSON, Nev., Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.
Oct 20, 2022 08:00 am ET
Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test
HENDERSON, Nev., Oct. 20, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the signing of a global supply agreement with a market leader in pet healthcare (the "Company").
Oct 11, 2022 08:05 am ET
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer
Sep 16, 2022 08:35 am ET
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN...
Sep 12, 2022 08:35 am ET
Life Sciences Virtual Investor Conference Agenda Announced for September 15th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors,...
Sep 12, 2022 08:35 am ET
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, today...
Aug 16, 2022 08:00 am ET
Volition Appoints Mickie Henshall as an Independent Director
HENDERSON, Nev., Aug. 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022.  Ms. Henshall was also appointed as a member of the Compensation Committee and the Nominations and Governance Committee.
Aug 10, 2022 04:10 pm ET
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, August 11, at 8:30 a.m. U.S. Eastern Time
Aug 10, 2022 08:00 am ET
Volition Announces U.S. Clinical Study for NETs
HENDERSON, Nev., Aug. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis.
Aug 08, 2022 08:00 am ET
Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy
HENDERSON, Nev., Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC ("DXOCRO") to undertake development and clinical validation studies for its Nu.Q® product portfolio in the United States.
Aug 03, 2022 08:00 am ET
VolitionRx Awarded $1.5 Million in Non-Dilutive Funding
HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.
Aug 03, 2022 07:00 am ET
VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference
Henderson, Nevada--(Newsfile Corp. - August 3, 2022) - VolitionRx Limited (NYSE American: VNRX) today announced that company executives Cameron Reynolds, CEO, and Scott Powell, Head of Investor Relations, will be attending the Q3 Virtual Investor Summit. During the presentation, VolitionRx Limited's Chief Executive Officer, Cameron Reynolds, will highlight the Company's transformational business strategy, disruptive technology, noteworthy collaborations and partnerships, and the broader going-forward corporate vision. The presentation will be webcast and an archived recording will be made available in Investors' section of the VolitionRx Limited website.
Aug 02, 2022 04:10 pm ET
VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., Aug. 2, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the exercise in full of the underwriter's overallotment option, at a public offering price of $2.00 per share.  The gross proceeds to Volition from the offering were $6.9 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares of common stock sold
Aug 02, 2022 08:30 am ET
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics...
Aug 02, 2022 08:05 am ET
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the tr
Jul 29, 2022 08:30 am ET
VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the offering a 30-day option to purchase up to an additional 450,000
Jul 28, 2022 04:10 pm ET
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
HENDERSON, Nev., July 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock.  All of the shares of common stock are being offered by Volition.  In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.  The final terms of the proposed offer
May 31, 2022 08:00 am ET
Volition Achieves CE Mark for Nu.Q® NETs Test
to aid the detection and evaluation of diseases associated with NETosis
May 11, 2022 04:10 pm ET
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time
May 06, 2022 08:00 am ET
VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern TimeCapital Markets Day Friday May 13 at 10:00 a.m. Eastern Time
May 05, 2022 08:03 am ET
VolitionRx Limited to Host Capital Markets Day on Friday May 13
AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company plans to host a Capital Markets Day in a hybrid format on  Friday, May 13, 2022, at 10 a.m. U.S. Eastern Time.  Volition's executive team will provide strategic updates and discuss the Company's key short-term growth drivers.
Apr 25, 2022 08:00 am ET
Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare
AUSTIN, Texas, April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, has announced the launch of its Nu.Q® Vet Cancer Test in Asia through its appointed distributor SAGE Healthcare Private Limited.
Apr 06, 2022 08:00 am ET
Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head of Quality and Development Process.
Mar 30, 2022 04:10 pm ET
VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00am U.S. Eastern Time ·       
Mar 29, 2022 08:00 am ET
Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer Screen
LOVELAND, Colo., March 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, has announced an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") to adapt and commercialize the Nu.Q® Vet Cancer Screening Test at the point of care for companion animals on Heska's technology.
Mar 29, 2022 08:00 am ET
Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care
AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) ("Heska") to sell its Nu.Q® Vet Cancer Screening Test at the point of care for companion animals. Heska is a leading global provider of advanced veterinary diagnostics.
Mar 28, 2022 04:25 pm ET
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time
Mar 22, 2022 09:50 am ET
Sidoti March Virtual Small Cap Investor Conference
NEW YORK, NY / ACCESSWIRE / March 22, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small Cap Virtual Conference taking place Wednesday and Thursday, March 23rd-24th, 2022. The links can also be found at www.sidoticonference.com/events.
Mar 14, 2022 08:35 am ET
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the March 10th Life Sciences Investor Forum are now available for on-demand viewing. REGISTER OR LOGIN NOW AT:...
Mar 08, 2022 08:35 am ET
UPDATE – Life Sciences Investor Forum: Company Executives Present Live March 10th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10th. This virtual event will showcase live company presentations and interactive...
Mar 07, 2022 08:35 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10th. This virtual event will showcase live company presentations and interactive...
Jan 20, 2022 07:30 am ET
Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas
AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, and thereby reduce unnecessary colonoscopies. The studies also demonstrated that the company's Nu.Q® assays can improve the detection of high-risk adenomas in asymptomatic patients.
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing.
Dec 16, 2021 07:00 am ET
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia
SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcare into centralized labs in other key Asian markets. Volition's global strategy is to implement similar agreements with multiple companies to ensure the broadest possible accessibility to the Nu.Q® Test worldwide. Volition continues to make significant progress in ongoing negotiations with the multi-nati
Dec 14, 2021 07:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com
Dec 09, 2021 11:19 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.
Dec 07, 2021 04:30 pm ET
Sidoti December Micro Cap Virtual Conference
Presentation Times Released for 75+ Presenting Companies
Nov 15, 2021 09:00 am ET
Diamond Equity Research Emerging Growth Invitational Winter 2021 Spotlight Virtual Conference
Investors can register at https://www.diamondequityresearch.com/conferences/ or using the company specific links below. Virtual Agenda – Tuesday, November 16, 2021 9:00am-9:30amVolitionRX Limited (NYSE: VNRX)9:40am-10:10amEqonex Limited (NASDAQ:...
Nov 10, 2021 03:10 pm ET
VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time
Nov 08, 2021 07:30 am ET
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providing a business update.
Nov 05, 2021 12:00 pm ET
Sidoti Microcap Virtual Conference
A Conference Open to All Classes of Investors70+ Companies Presenting and Meeting Interested Investors 1x1Wednesday and Thursday, December 8-9, 2021
Nov 04, 2021 08:33 am ET
Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference
Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs. Paves the way for second Nu.Q® Vet product launch planned for 2022. A second abstract details the first use of Nu.Q® Capture, Volition's enrichment tool, in the plasma of dogs with lymphoma. AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering
Sep 20, 2021 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations and...
Sep 10, 2021 08:35 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Aug 18, 2021 08:45 am ET
Sidoti Microcap Virtual Conference
Presentation Times Released for 50 Presenting CompaniesWednesday and Thursday, August 18-19, 2021
Aug 12, 2021 09:00 am ET
Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference
Investors can register at https://www.diamondequityresearch.com/conferences/ or using the company specific links below. Agenda – August 17th, 2021 9:00-9:30VolitionRX Limited (NYSE:VNRX)9:40-10:10Blue Star Foods Corp. (OTC:BSFC)10:20-10:50Color...
Aug 11, 2021 04:10 pm ET
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
Strong balance sheet with approximately $27.9 million in cash and cash equivalents Strengthened the Company's veterinary leadership team to drive commercial focus Expanded the Company's intellectual property portfolio Published two clinical papers Continued focus on, and made strong progress towards, product launches and licensing in both the human and veterinary spaces worldwide AUSTIN, Texas, Aug. 11, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2021. Volition manage
Aug 04, 2021 08:15 am ET
VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2021, in addition to providing a business update.
Jul 22, 2021 08:00 am ET
Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring
AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with researchers at two leading  NHS Foundation Trusts on two studies in COVID-19 for which abstracts were released this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2021.
Jun 28, 2021 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
Jun 22, 2021 04:45 pm ET
Sidoti Summer Virtual Small-Cap Conference
Presentation Times and Weblinks Released for Approximately 70 Presenting Companies
Jun 21, 2021 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Jun 21, 2021 08:35 am ET
VolitionRx Limited to Webcast Live at Life Sciences Investor Forum June 24th
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, today...
May 18, 2021 05:30 pm ET
Mar 29, 2021 08:35 am ET
Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the March 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
Mar 23, 2021 07:30 pm ET
Sidoti Virtual Investor Conference
Presentation Times and Weblinks Released for Over 125 Presenting Companies
Mar 22, 2021 08:35 am ET
VolitionRx Limited to Webcast Live at Life Sciences Investor Forum March 25th
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, today...
Mar 19, 2021 04:24 pm ET
VolitionRx Limited Announces Participation in the Benzinga Biotech Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - March 19, 2021) - VolitionRx Limited (NYSE: VNRX) will be presenting at the Benzinga Biotech Small Cap Conference taking place on March 24-25, 2021. We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.
Mar 19, 2021 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live March 25th, 2021
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Feb 12, 2021 08:25 am ET
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its underwritten public offering of 3,809,524 shares of its common stock (the "Offering") for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of
Feb 10, 2021 08:18 am ET
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, Feb. 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced the pricing of its underwritten public offering of 3,809,524 shares of its common stock (the "Offering") for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition.  All of the
Feb 09, 2021 03:01 pm ET
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
AUSTIN, Texas, Feb. 9, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it is commencing an underwritten public offering of its common stock (the "Offering").  All of the shares to be sold in the Offering will be sold by Volition, subject to customary closing conditions. In addition, Volition intends to grant the underwriter for th
Feb 08, 2021 07:35 am ET
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Feb 08, 2021 07:35 am ET
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 4th Small and Microcap Showcase are now available for on-demand viewing.
Feb 02, 2021 06:45 am ET
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
AUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided a business update and announced the appointment of a new Chief Financial Officer, Mr. Terig Hughes, in addition to the appointment of Dr. Gaetan Michel as Chief Operating Officer, Mr. Gael Forterre as Chief Commercial Officer, and Dr. Mark Eccleston as Chief Technology Officer.
Feb 01, 2021 02:29 pm ET
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com February 4th
AUSTIN, Texas, Feb. 1, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, today announced that Scott Powell, EVP of Investor Relations and Chief Financial Officer of Volition America Inc., will present live at VirtualInvestorConferences.com on February 4th.   
Jan 28, 2021 07:35 am ET
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jan 28, 2021 07:35 am ET
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small and Microcap Showcase.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, February 4th  with the first live webcast at 9:00 AM ET.
Jan 28, 2021 05:15 am ET
National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer
AUSTIN, Texas, Jan. 28, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has an abstract presented today at the world's largest lung cancer meeting, the WCLC, which is being held virtually this year.
Jan 25, 2021 07:45 am ET
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes, Belgium. Volition plans to utilize this facility to produce, at large scale, all the key raw materials for its Nu. Q™ products, such as recombinant nucleosomes and antibodies. Volition will also use the facility to manufacture finished products such as the recently launched Nu.Q™ Vet Cancer Screening Test and t
Jan 13, 2021 07:00 am ET
Sidoti Virtual Investor Conference
Presentation Times and Weblinks Released for Over 60 Presenting Companies
Jan 06, 2021 07:25 am ET
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the Walloon Region and Namur Invest, Belgium. To date, Agencies from the Walloon Region have awarded Volition an aggregate of approximately $13 million in non-dilutive funding including this most recent award. This additional funding consisted of a cash grant of $1.3 million and $2.7 million in loans.
Dec 21, 2020 08:35 am ET
Life Sciences Company Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
Dec 14, 2020 08:28 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Dec 03, 2020 07:30 am ET
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
AUSTIN, Texas, Dec. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Dr. Tom Butera DVM, to the Company's Board of Directors, effective December 1, 2020. Dr. Butera was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees.
Dec 01, 2020 07:45 am ET
Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the launch of its first product, the Nu.Q™ Vet Cancer Screening Test.
Nov 19, 2020 06:45 am ET
Sidoti Virtual Microcap Investor Conference
NEW YORK, NY / ACCESSWIRE / November 19, 2020 / Sidoti & Company, LLC proudly releases the presentation schedule, with weblink click-throughs, for today's Virtual Microcap Investor Conference.
Nov 19, 2020 06:00 am ET
VolitionRx Limited to Present COVID-19 Data at MEDICA 2020
AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, has announced that Dr. Mark Eccleston, a founding scientist and Business Development Director at Volition, will today present preliminary results from its proof of concept clinical studies focused on monitoring disease progression of COVID-19 as part of the "Innovative COVID-19 Diagnostics" session at the virtual MEDICA LABMED FORUM.
Nov 12, 2020 03:10 pm ET
VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update
Launch of first product, the Nu.Q™ Vet Cancer Screening Test planned for November 30, 2020 Engaged Diagnostic Oncology CRO LLC to conduct U.S. clinical trial for Non-Hodgkin's Lymphoma Expanded research program for the use of Nu.Q™ technology in NETosis AUSTIN, Texas, Nov. 12, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2020. Volition management will host a conference call tomorrow, November 13 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference ca
Nov 10, 2020 07:00 am ET
Volition Veterinary Presents Expert Report Ahead of First Product Launch
A Look to the Future of Cancer Diagnostics compiles insight from four veterinary cancer experts Report provides insight into the clinical impact of early cancer detection, and recent advances Experts also reviewed data on the Nu.Q™ Vet Cancer Screening Test, providing opinion and guidance ahead of expected launch Download a copy of the report here AUSTIN, Nov. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in
Nov 09, 2020 07:00 am ET
VolitionRx Limited Schedules Third Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 9, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, November 13, at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter 2020, in addition to providing a business update.
Oct 21, 2020 08:00 am ET
VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 21, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital markets day event yesterday and today releases a video of that event.
Oct 20, 2020 07:00 am ET
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will host a capital markets day event today,  Tuesday, October 20, 2020, starting at 8:00 a.m. Eastern Time.  To join the event LIVE please register here.
Oct 16, 2020 08:00 am ET
Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conf
Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year Cancer is the most common cause of death in dogs over the age of two years old in the U.S. Together, Lymphoma and Hemangiosarcoma make up approximately one-third of canine cancers AUSTIN, Texas, Oct. 16, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cance
Oct 14, 2020 08:00 am ET
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced further details of the capital markets day event it will host on Tuesday, October 20, 2020, starting at 8:00 a.m. Eastern Time.  To join the event LIVE please register here.
Sep 21, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Sep 14, 2020 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Aug 31, 2020 05:00 pm ET
(LD Micro) 360 Companies Set to Present - this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 16, 2020 11:00 am ET
'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st
LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.
Jul 14, 2020 06:00 am ET
Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
AUSTIN, Texas, July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today announced that results from two proof of concept clinical studies using its Nu.Q™ assays have been submitted for peer review and will be available on BIORXIV.ORG shortly. "Circulating Nucleosomes as potential prognostic markers for COVID-19 disease severity" .
Jul 09, 2020 09:00 am ET
Cotterford Co. Ltd. Sends Letter to VolitionRX Following Annual Meeting Vote Results Confirming Deep-Seated Discontent Among Shareholders
Cotterford Co. Ltd. (“Cotterford”) the beneficial owner of approximately 26% of the outstanding shares of VolitionRX Limited (“Volition”) (AMEX: VNRX), today sent a letter to the Board of Directors of the Company regarding the voting results of Volition’s 2020 Annual Meeting and the Company’s path forward.
Jun 25, 2020 08:45 am ET
VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
AUSTIN, Texas, June 25, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, today released a business update video and announced that it will be added to both the Russell 3000® and Russell Microcap® Indexes at the conclusion of the 2020 Russell indexes' annual reconstitution, effective at the close of trading tomorrow, June 26, 2020, based on a preliminary list of additions initially made public on June 5, 2020.
Jun 10, 2020 09:34 am ET
Cotterford Co. Ltd. Sends Letter to Board of VolitionRX
June 10, 2020 – Cotterford Co. Ltd. (“Cotterford”) the beneficial owner of approximately 29.3% of the outstanding shares of VolitionRX Limited (“Volition”) (AMEX: VNRX), as of the record date for the Company’s 2020 Annual Meeting, today sent a letter to the Board of Directors of the Company. 
May 27, 2020 08:45 am ET
Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
AUSTIN, May 27, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer, Cameron Reynolds has been invited to present at The Role of Cell Therapy and Clarity on Testing Conference organised by the Maxim Group.
May 22, 2020 04:01 pm ET
VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its previously announced underwritten public offering of an aggregate of 5,019,750 shares of common stock, including the exercise in full of the overallotment option, at a public offering price of $2.75 per share for total gross proceeds of $13.8 mil
May 20, 2020 08:45 am ET
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underwritten public offering. Volition is offering 4,365,000 shares of common stock, par value $0.001 per share, at a price to the public of $2.75 per share. In connection with the offering, Volition has also granted the unde
May 19, 2020 04:01 pm ET
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any.  All
May 13, 2020 05:00 pm ET
VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
AUSTIN, Texas, May 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), an epigenetics company developing simple, easy to use and cost effective blood tests to help diagnose a range of cancers, will present three abstracts at the 2020 ASCO Annual Meeting.
May 07, 2020 04:10 pm ET
VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
AUSTIN, Texas, May 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2020. Volition management will host a conference call tomorrow, May 8 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
May 05, 2020 08:30 am ET
VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, May 5, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business update.
Apr 29, 2020 08:30 am ET
Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
AUSTIN, Texas, April 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its first proof of concept study conducted by Texas A&M University ("TAMU"). At a specificity of 90%, a single Nu.Q™ Vet assay detected almost 70% of both Canine Hemangiosarcoma and Canine Lymphoma with Areas Under the Curve ("AUC") of 84.5% and 83.1% cancer versus healthy, respectively. These two cancers alone represent almost a third of all canine cancers.
Apr 23, 2020 08:30 am ET
Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infec
Nov 12, 2019 03:10 pm ET
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, Nov. 12, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2019. Volition management will host a conference call tomorrow, November 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
Nov 12, 2019 03:10 pm ET
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, Nov 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2019. Volition management will host a conference call tomorrow, November 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
Nov 07, 2019 07:30 am ET
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providing a business update.
Oct 29, 2019 08:30 am ET
Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video
AUSTIN, Texas, Oct. 29, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further $500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its subsidiary Volition Veterinary Diagnostics Development, LLC.
Oct 25, 2019 12:00 pm ET
Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC
AUSTIN, Texas, Oct. 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated by the previously announced Memorandum of Understanding with Texas A&M University ("Texas A&M"), a member of The Texas A&M University System, to collaborate on the research and development of certain veterinary diagnostic products.  
Oct 18, 2019 08:30 am ET
Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department will be presenting at the Veterinary Cancer Society ("VCS") Annual Conference in Houston taking place this weekend. The VCS Conference is one of the largest veterinary oncology meetings in the world with presentations from keynote speakers, b
Oct 09, 2019 04:05 pm ET
Volition Appoints Dr. Phillip Barnes to Board of Directors
AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effective October 9, 2019. Dr. Barnes was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. As a non-executive member of the Company's Board, Dr. Barnes will provide independent expertise and strategic counsel to VolitionRx in connection with the planned commercialization of its Nu.QTM blood-based diagnostic platform.
Sep 17, 2019 08:35 am ET
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could be used in two ways, firstly to increase specificity in Volition's current assays by removing the background signal and secondly, as an enabling technology in sequencing-based liquid biopsies by enriching nucleosomes of cancer origin from the blood.
Aug 12, 2019 04:05 pm ET
VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, Aug. 12, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2019. Volition management will host a conference call tomorrow, August 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
Aug 08, 2019 08:30 am ET
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expert Nathan Dewsbury as its Chief Executive Officer.  A video regarding this announcement can be viewed here.
Aug 07, 2019 08:45 am ET
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Tuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business update.
Jul 24, 2019 04:05 pm ET
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase $4.8 million in aggregate amount of shares of our common stock (at $3 per share of common stock).  With this exercise, the investor has fully-exercised the warrant to purchase 5 million shares of common stock that was originally issued in the private placement (PIPE) completed in August 2018.  
Jul 18, 2019 08:30 am ET
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer.
Jul 10, 2019 08:30 am ET
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, Belgium.  To date, Agencies from the Region have awarded Volition an aggregate of approximately $6 million in non-dilutive funding including this most recent award.
May 08, 2019 04:05 pm ET
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2019. Volition management will host a conference call tomorrow, May 9, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
May 07, 2019 08:30 am ET
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 wit
May 06, 2019 04:05 pm ET
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call on Thursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update.
Apr 19, 2019 08:10 am ET
Recent Analysis Shows Roku, AMERI, Kforce, VolitionRX, Xinyuan Real Estate, and TSR Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roku, Inc. (NASDAQ:ROKU), AMERI Holdings, Inc. (NASDAQ:AMRH), Kforce,...
Apr 09, 2019 05:17 pm ET
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. Volition has also issued a Company Update Report; a downloadable version of which is available here
Apr 09, 2019 08:30 am ET
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.  Any such relationship is subject to the negotiation of terms and conditions and the entry into a final binding agreement.  The MOU contemplates that Belgian Volition would form a
Apr 03, 2019 08:30 am ET
VolitionRx Limited Extends Clinical Trial Program in Lung Cancer
ISNES, Belgium, April 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed To
Mar 25, 2019 08:40 am ET
VolitionRx Limited to Present at Conferences in March & April 2019
ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019.
Mar 15, 2019 08:30 am ET
VolitionRx Limited to Present at Conferences in the U.S. Next Week
ISNES, Belgium, March 15, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr. Cameron Reynolds, is scheduled to present at two conferences in the U.S. next week.
Mar 13, 2019 04:05 pm ET
VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update
ISNES, Belgium, March 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year ended December 31, 2018. Volition management will host a conference call tomorrow, March 14, at 8:30a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
Mar 07, 2019 07:30 am ET
VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update
ISNES, Belgium, March 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2018.
Nov 14, 2018 08:50 am ET
New Research Coverage Highlights Kandi Technologies Group, AquaVenture, Bridgeline Digital, VolitionRX, USD Partners LP, and ZK International Group Co. — Consolidated Revenues, Company Growth, and Exp
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Kandi Technologies Group, Inc. (NASDAQ:KNDI), AquaVenture Holdings Ltd....
Nov 07, 2018 03:05 pm ET
VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update
ISNES, Belgium, Nov. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended September 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, November 8, at 8:30 AM U.S. Eastern Time.
Oct 31, 2018 04:30 pm ET
VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update
Conference call to take place Thursday, November 8, 2018 at 8:30 am Eastern time
Oct 04, 2018 09:00 am ET
VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics
ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belgian Technology Mission at Texas A&M University. The meeting was sponsored in part by the Wallonia Export-Investment Agency (AWEX), a long-time supporter of Volition in Belgium.
Sep 26, 2018 09:00 am ET
VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board
ISNES, Belgium, Sept. 26 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today released a video featuring members of its Scientific Advisory Board (SAB). The video was taken at Volition's laboratories in Belgium during the last SAB meeting and features members of the SAB discussing their involvement with Volition and support of its mission to significantly improve cancer diagnostics.
Sep 05, 2018 08:30 am ET
VolitionRx Limited to Attend Multiple Conferences in September
ISNES, Belgium, Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds and/or its Executive Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at multiple conferences in September.
Aug 13, 2018 04:05 pm ET
VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 14, at 8:30 AM U.S. Eastern Time.
Aug 13, 2018 08:30 am ET
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer.
Aug 09, 2018 08:30 am ET
VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study
ISNES, Belgium, Aug. 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform technology for the diagnosis of endometriosis through a simple blood test. Volition has now commenced running its discovery grade assays through the cohorts and expects to report preliminary data over the coming months.
Aug 08, 2018 06:00 am ET
VolitionRx Announces $9 Million Private Placement
ISNES, Belgium, Aug. 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a definitive agreement with an existing accredited investor related to a private placement offering (PIPE) of 5 million shares of Volition common stock at a price of $1.80 per share, as well as a warrant to purchase up to an additional 5 million shares of Volition common stock at an exercise price of $3.00 per share payable in cash, which will result in gross proceeds to Volition before the deduction of estimated offering expenses of $9 million (excludin
Aug 07, 2018 08:35 am ET
VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update
ISNES, Belgium, Aug. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Tuesday, August 14 at 8:30 a.m. Eastern time to discuss its financial and operating results from the second quarter of 2018, in conjunction with the filing of its quarterly report on Form 10-Q for the second quarter ended June 30, 2018.
Aug 01, 2018 07:00 am ET
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
ISNES, Belgium, Aug. 1, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its first product the "Total Nu.Q™ Assay" research use only (RUO) kit, is ready and available for purchase through Active Motif, its Global Sales and Distribution Partner (https://www.activemotif.com/catalog/1266/NuQ-total-assay). This kit, based on Volition's proprietary Nucleosomics® technology, is the first in a range of kits due to be released over the coming months.
Jul 10, 2018 08:30 am ET
Volition Extends Global Reach of its Clinical Trial Program
ISNES, Belgium, July 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its already impressive clinical trial program with the execution of additional agreements to conduct large-scale colorectal cancer research studies across the Asia Pacific Region. These multi-country, multi-center and multi-ethnic Asian subject cohorts are in addition to the approximate 45,000 European subject cohorts and the 13,500 plus U.S. subject cohorts that are already part of existing studies and further demonstrate Volition's commitment to commercia
Jul 02, 2018 08:30 am ET
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
ISNES, Belgium, July 2, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding of approximately $700,000 from the Walloon Regional Government. Including this latest amount, Volition has received approximately $3.7 million in non-dilutive funding from a number of local agencies to date.
May 14, 2018 09:00 am ET
VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018
ISNES, Belgium, May 14, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced its participation in the Bank of America Merrill Lynch 2018 Health Care Conference being held from May 15-17, 2018 at the Encore Hotel in Las Vegas, NV.
May 10, 2018 04:05 pm ET
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2018. Volition management will host a conference call tomorrow, May 11, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.
May 09, 2018 09:00 am ET
VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
ISNES, Belgium, May 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a Global Sales and Distribution Agreement with Active Motif for a range of Research Use Only ("RUO") kits, that are based on its proprietary Nucleosomics® technology.
May 04, 2018 08:00 am ET
VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update
Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time
Mar 13, 2018 04:05 pm ET
VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock
ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:  VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share for gross proceeds of $8.4 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition.  All of the shares of common st
Mar 09, 2018 08:10 am ET
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
ISNES, Belgium, March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the pricing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share. The gross proceeds to Volition from this offering are expected to be approximately $8.4 million, before deducting underwriting discounts and commissions and other estimated o
Mar 08, 2018 03:01 pm ET
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
NAMUR, Belgium, March 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any.  All shares of common stock in the offering are being offered by
Mar 07, 2018 07:30 am ET
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University.
Mar 01, 2018 03:05 pm ET
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, March 2 at 8:30 a.m. Eastern Time
Feb 28, 2018 03:05 pm ET
VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update
Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time
Feb 26, 2018 03:05 pm ET
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
Study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer screening trial for Nu.QTM blood test Conference call to discuss interim results scheduled for Tuesday, February 27 at 8:30 a.m. Eastern Time ISNES, Belgium, Feb. 26, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study. This ongoing study is being carried out in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subj
Feb 05, 2018 07:30 am ET
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group.  The study was established to answer the very practical, logistical questions of how a triage blood test could fit into the current Danish screening program for colorectal cancer ("CRC"). The study showed that it was indeed possible to collect, process, gather and ship the blood test from all five participating hospitals to a central laboratory within
Jan 03, 2018 07:30 am ET
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone
ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO, Cameron Reynolds updating the company's shareholders.
Nov 10, 2017 07:30 am ET
Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies
ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. Subject to agreement on the terms and conditions, the Parties intend to sign a binding CRC Study Agreement in the first quarter of 2018.  
Nov 09, 2017 04:05 pm ET
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017. Volition management will host a conference call tomorrow, November 10, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.